EMN 2018 | Therapeutically targeting mutations in myeloma: NF-κB, t(4;14) and BRAF
As our knowledge of the genetics of multiple myeloma (MM) advances, we can more precisely understand and target the disease. Here, Martin Kaiser, MD, of the Institute of Cancer Research, London, UK, discusses how different classes of genetic abnormalities in MM could be targeted. Dr Kaiser highlights exciting work on the t(4;14) translocation in MM and tissue agnostic therapies.This video was recorded at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.
Get great new content delivered to your inboxSign up